PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 5:17 AM ET

Sponsor Check › Person

DS
No photo found yet (own website and image search run after this page is viewed)

David Sidransky

Named as an officer, director or promoter on SEC Form D filings · NJ, MO, Israel (as filed: L3), United Kingdom (as filed: X0), MD, NY, CA · Mar 3, 2011 → Jul 24, 2019

12deals (issuers)
$458.6Mreported sold
372investors
35Form D filings
2011–2019years on file
Follow this personLook further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:23 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

David Sidransky is listed as an executive officer and director on 35 SEC Form D filings by 12 issuers between Nov 2009 and Mar 2024. Largest by amount reported sold: K-V Pharmaceutical Co (Chesterfield, MO — pharmaceuticals — 2010–2011; $260.9M reported sold to 104 investors), Akari Therapeutics Plc (Tampa, FL — other health care — 2012–2013; $75M reported sold to 62 investors), Israel Biotech Fund II, L.P. (Rehovot, Israel (as filed: L3) — pooled investment fund — 2019; $65M reported sold to 44 investors), Orgenesis Inc. (Germantown, MD — biotechnology — 2014–2024; $14.8M reported sold to 46 investors), CHAMPIONS ONCOLOGY, INC. (Hackensack, NJ — biotechnology — 2013–2015; $14M reported sold to 13 investors) and 7 more (all listed below).

What this means That is a lot of deals — 12 separate companies raised money with this person listed as executive officer and director, over about 15 years. Across those companies the filings report $458.6M sold in total.

Listed alongside Kenneth Berlin (8 shared filings), Tali Yaron-Eldar (7 shared filings), Vered Caplan (7 shared filings), Yaron Adler (7 shared filings), Brian A Markison (6 shared filings) and 98 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around David. Each name links to their own page.

2 of the issuers belong to the sponsor group Israel Biotech (2 issuers, $65M reported sold, 2015–2019).

What this means A sponsor group is one team that sets up a new company for each deal. Israel Biotech has 2 companies on file and $65M reported sold in total — the group page shows the whole track record in one place.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.

What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.

We compared 35 public filings for David Sidransky and found 10 differences, 2 worth asking the sponsor about: Paid seller listed without a CRD number: Mio Capital Ltd; 4 Form Ds were filed more than 15 days after the first sale; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for David Sidransky has not run yet — it is joining a line of 12,069 names; searches run around the clock at the hosts' allowed rate. Searched so far: 27 names.

Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:23 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: AZ, CA, DE, TX, WA (crawled Oct 23, 2026)

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched David Sidransky..

State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states are not covered.

3. Bankruptcies

None found in sources searched — federal bankruptcy courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:23 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

10 differences found between the filings for David Sidransky — 2 worth asking about (compared 35 filings on Oct 24, 2026)

Worth asking · Jan 29, 2020

Paid seller listed without a CRD number: Mio Capital Ltd. — Orgenesis Inc.

Mio Capital Ltd. is listed as receiving sales compensation on 1 filing (Jan 29, 2020) with no FINRA CRD number given.

What this means People paid to sell securities normally hold a FINRA registration with a CRD number. Without one we cannot look them up on BrokerCheck. Ask who they are and whether they are registered.

Form D · Jan 29, 2020 ↗BrokerCheck search: Mio Capital Ltd. ↗Orgenesis Inc. — PartnerFacts page ↗
Sources
Worth asking · Nov 17, 2010 – Dec 28, 2015

4 Form Ds were filed more than 15 days after the first sale

Form D filed 92 days after the first sale — Rosetta Genomics Ltd. · Form D filed 18 days after the first sale — Orgenesis Inc. · Form D filed 31 days after the first sale — IMMUNE PHARMACEUTICALS INC · Form D filed 19 days after the first sale — K-V Pharmaceutical Co

What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.

Form D · Mar 3, 2011 ↗Rosetta Genomics Ltd. — PartnerFacts page ↗Form D · Dec 28, 2015 ↗Orgenesis Inc. — PartnerFacts page ↗
Sources
Note · Jan 29, 2020 – Apr 14, 2022

David Sidransky's role changed at Orgenesis Inc.: executive officer → director

The Jan 29, 2020 filing lists David Sidransky as executive officer; the Apr 14, 2022 Form D lists director.

What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.

Form D · Jan 29, 2020 ↗Form D · Apr 14, 2022 ↗David Sidransky — PartnerFacts page ↗Orgenesis Inc. — PartnerFacts page ↗
Sources
Note · Feb 8, 2018 – Jan 29, 2020

David Sidransky's role changed at Orgenesis Inc.: director → executive officer

The Feb 8, 2018 filing lists David Sidransky as director; the Jan 29, 2020 Form D lists executive officer.

What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.

Form D · Feb 8, 2018 ↗Form D · Jan 29, 2020 ↗David Sidransky — PartnerFacts page ↗Orgenesis Inc. — PartnerFacts page ↗
Sources
Note · May 20, 2016 – Dec 30, 2016

Offering amount changed between filings — TAMIR BIOTECHNOLOGY, INC.

The May 20, 2016 filing says $1,622,477 offered; the Dec 30, 2016 Form D/A says $1,722,476.

What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.

Form D (earlier) · May 20, 2016 ↗Form D/A (later) · Dec 30, 2016 ↗TAMIR BIOTECHNOLOGY, INC. — PartnerFacts page ↗
Sources
Note · Oct 19, 2011 – Jul 24, 2019

8 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — Israel Biotech Fund II, L.P. (latest filing Jul 24, 2019) · No amendment in the last 12 months on an offering that may still be open — Orgenesis Inc. (latest filing Feb 8, 2018) · No amendment in the last 12 months on an offering that may still be open — TAMIR BIOTECHNOLOGY, INC. (latest filing Jan 25, 2018) · No amendment in the last 12 months on an offering that may still be open — Galmed Pharmaceuticals Ltd. (latest filing Aug 15, 2017) · No amendment in the last 12 months on an offering that may still be open — Orgenesis Inc. (latest filing Dec 28, 2015) · and 3 more

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Form D · Jul 24, 2019 ↗Israel Biotech Fund II, L.P. — PartnerFacts page ↗Form D · Feb 8, 2018 ↗Orgenesis Inc. — PartnerFacts page ↗
Sources
Note · Nov 2, 2009 – Jan 25, 2018

5 address changes between filings

Address moved from San Diego, CA to Short Hills, NJ — TAMIR BIOTECHNOLOGY, INC. · Address moved from White Plains, NY to Germantown, MD — Orgenesis Inc. · Address moved from Somerset, NJ to San Diego, CA — TAMIR BIOTECHNOLOGY, INC. · Address moved from New York, NY to London, United Kingdom (as filed: X0) — Akari Therapeutics Plc · Address moved from London, United Kingdom (as filed: X0) to New York, NY — Akari Therapeutics Plc

What this means Businesses move. If you were told one city and the forms say another, ask which is current.

Form D/A · Dec 30, 2016 ↗Form D · Jan 25, 2018 ↗TAMIR BIOTECHNOLOGY, INC. — PartnerFacts page ↗Form D · Jul 9, 2014 ↗
Sources
Note · Nov 2, 2009 – Mar 14, 2024

David Sidransky is listed with 7 different address states: NJ, MO, L3, MD, X0, NY, CA

NJ on 7 filings (Nov 2, 2009 to Nov 2, 2023); MO on 3 filings (Dec 6, 2010 to Apr 1, 2011); Israel (as filed: L3) on 12 filings (Mar 3, 2011 to Jul 24, 2019); MD on 7 filings (Aug 26, 2013 to Mar 14, 2024); United Kingdom (as filed: X0) on 1 filing (Sep 30, 2013); NY on 2 filings (Apr 14, 2014 to Jul 9, 2014); CA on 3 filings (Sep 10, 2015 to Dec 30, 2016).

What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.

Form D · Nov 2, 2009 ↗Form D · Dec 6, 2010 ↗Form D · Mar 3, 2011 ↗Form D · Aug 26, 2013 ↗
Sources
Note · Apr 28, 2021 – Nov 2, 2023

Reported revenue range changed between filings — Ayala Pharmaceuticals, Inc.

"$1,000,001 - $5,000,000" (Apr 28, 2021); then "Decline to Disclose" (Nov 2, 2023).

What this means This is the size band the issuer picks for itself on the form. A change can mean the business grew or shrank — or that it chose not to say. Ask for current numbers.

Form D · Apr 28, 2021 ↗Form D · Nov 2, 2023 ↗Ayala Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Note · Jul 9, 2014 – Sep 8, 2023

Reported revenue range changed between filings — Orgenesis Inc.

"Decline to Disclose" (Jul 9, 2014); then "Not Applicable" (Sep 8, 2023).

What this means This is the size band the issuer picks for itself on the form. A change can mean the business grew or shrank — or that it chose not to say. Ask for current numbers.

Form D · Jul 9, 2014 ↗Form D · Sep 8, 2023 ↗Orgenesis Inc. — PartnerFacts page ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

11 of 32 offerings report sales commissions totalling $3,822,950; 5 report finder's fees totalling $11,574,320; 3 report proceeds to related persons totalling $376,000. (includes amounts the issuer reported as estimates)

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Mar 14, 2024 D
Orgenesis Inc.
File 021-507589
$0$0$0None listed on this filingEDGAR ↗
Nov 2, 2023 D
Ayala Pharmaceuticals, Inc.
File 021-496373
$0$0$0None listed on this filingEDGAR ↗
Sep 8, 2023 D
Orgenesis Inc.
File 021-491704
$0$0$0None listed on this filingEDGAR ↗
Apr 14, 2022 D
Orgenesis Inc.
File 021-441778
$0$0$0None listed on this filingEDGAR ↗
Feb 11, 2022 D
Ayala Pharmaceuticals, Inc.
File 021-433189
$0$295,000$0
The proceeds from the offering will not be used for payments to any of the persons identified as related persons in response to Item 3.
A.G.P./Alliance Global Partners BrokerCheck CRD 8361 ↗EDGAR ↗
Apr 28, 2021 D
Ayala Pharmaceuticals, Inc.
File 021-397547
$0$1,104,501$0
The proceeds from the offering will not be used for payments to any of the persons identified as related persons in response to Item 3.
A.G.P./Alliance Global Partners BrokerCheck CRD 8361 ↗EDGAR ↗
Jan 29, 2020 D
Orgenesis Inc.
File 021-359236
$739,200$0$0Mio Capital Ltd. no CRD number reported
via Bean Capital Limited
EDGAR ↗
Jul 24, 2019 D
Israel Biotech Fund II, L.P.
File 021-344933
$0$0$0 (est.)
Issuer pays an annual management fee to the General Partner of the Issuer.
None listed on this filingEDGAR ↗
Feb 8, 2018 D
Orgenesis Inc.
File 021-305225
$60,000 (est.)$0$0 (est.)Phoenix Financial Inc. BrokerCheck CRD 144403 ↗EDGAR ↗
Jan 25, 2018 D
TAMIR BIOTECHNOLOGY, INC.
File 021-304146
$0$0$0None listed on this filingEDGAR ↗
Aug 15, 2017 D
Galmed Pharmaceuticals Ltd.
File 021-292864
$0$0$0
Issuer expects to use proceeds from the offering for among other things general corporate purposes which includes payment of salaries to executive officers.
None listed on this filingEDGAR ↗
Dec 30, 2016 D/A
TAMIR BIOTECHNOLOGY, INC.
File 021-263556
$0$0$0None listed on this filingEDGAR ↗
Dec 28, 2015 D
Orgenesis Inc.
File 021-253961
$0$0$0 (est.)None listed on this filingEDGAR ↗
Oct 22, 2015 D
Israel Biotech Fund I, L.P.
File 021-249881
$0$0$0 (est.)
Issuer pays an annual management fee to the General Partner of the Issuer.
None listed on this filingEDGAR ↗
Sep 10, 2015 D
TAMIR BIOTECHNOLOGY, INC.
File 021-247388
$0$0$0None listed on this filingEDGAR ↗
Mar 25, 2015 D
CHAMPIONS ONCOLOGY, INC.
File 021-236631
$640,500$0$0MTS Securities, LLC BrokerCheck CRD 104059 ↗EDGAR ↗
Jul 9, 2014 D
Orgenesis Inc.
File 021-220643
$0$0$0None listed on this filingEDGAR ↗
Apr 14, 2014 D
IMMUNE PHARMACEUTICALS INC
File 021-215479
$544,558$0$0 (est.)Chardan Capital Markets LLC BrokerCheck CRD 120128 ↗EDGAR ↗
Sep 30, 2013 D
Akari Therapeutics Plc
File 021-203753
$876,136$0$180,000 (est.)
For back pay and reimbursement of expenses for officers.
MTS Securities, LLC BrokerCheck CRD 104059 ↗
Oppenheimer & Co. Inc. BrokerCheck CRD 249 ↗		EDGAR ↗
Aug 26, 2013 D
Y Labs, Inc.
File 021-201870
$0$0$0None listed on this filingEDGAR ↗
Feb 7, 2013 D
CHAMPIONS ONCOLOGY, INC.
File 021-191496
$0$0$0None listed on this filingEDGAR ↗
Feb 1, 2013 D
Akari Therapeutics Plc
File 021-191249
$74,480 (est.)$0$0Garden State Securities, Inc. BrokerCheck CRD 10083 ↗EDGAR ↗
Dec 13, 2012 D/A
Akari Therapeutics Plc
File 021-188250
$350,600 (est.)$0$0Garden State Securities, Inc. BrokerCheck CRD 10083 ↗EDGAR ↗
Apr 13, 2012 D
Akari Therapeutics Plc
File 021-176706
$0$0$111,000 (est.)
Amounts are for payment of salaries for executives
N/A no CRD number reportedEDGAR ↗
Feb 9, 2012 D
Rosetta Genomics Ltd.
File 021-173185
$102,851 (est.)$0$85,000 (est.)Aegis Capital Corp BrokerCheck CRD 15007 ↗EDGAR ↗
Nov 1, 2011 D
Rosetta Genomics Ltd.
File 021-168093
$91,125$0$0Rodman & Renshaw, LLC BrokerCheck CRD 16415 ↗EDGAR ↗
Apr 1, 2011 D
K-V Pharmaceutical Co
File 021-157753
$0$8,026,875 (est.)$0Jefferies and Company, Inc. BrokerCheck CRD 3247 ↗EDGAR ↗
Mar 7, 2011 D/A
Rosetta Genomics Ltd.
File 021-156181
$180,000$0$0Rodman & Renshaw, LLC BrokerCheck CRD 16415 ↗EDGAR ↗
Mar 7, 2011 D/A
Rosetta Genomics Ltd.
File 021-156186
$163,500$0$0Rodman & Renshaw, LLC BrokerCheck CRD 16415 ↗EDGAR ↗
Mar 4, 2011 D
K-V Pharmaceutical Co
File 021-156249
$0$1,940,250 (est.)$0Jefferies and Company, Inc. BrokerCheck CRD 3247 ↗EDGAR ↗
Dec 6, 2010 D
K-V Pharmaceutical Co
File 021-151410
$0$207,694$0Jefferies and Company, Inc. BrokerCheck CRD 3247 ↗EDGAR ↗
Nov 2, 2009 D
TAMIR BIOTECHNOLOGY, INC.
File 021-70871-7N
$0$0$0
Proceeds from the offering will be used for general working capital.
None listed on this filingEDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 12

Every issuer that named David Sidransky on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

O
Biotechnology

Orgenesis Inc.

Germantown, MD · Jul 9, 2014 → Mar 14, 2024 · 7 filings
  • Mar 14, 2024 · D · $2,340,903 sold of $2,340,903 · 46 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 8, 2023 · D · $1,000,000 sold of $1,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 14, 2022 · D · $14,800,000 sold of $14,800,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 29, 2020 · D · $9,240,000 sold of $9,240,000 · 5 investors · min. No minimum reported · role: Executive Officer EDGAR ↗
  • Feb 8, 2018 · D · $1,200,000 sold of Indefinite · 16 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 28, 2015 · D · $5,300,000 sold of $10,000,000 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 9, 2014 · D · $24,011 sold of $24,011 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $14.8M from 46 investors (100% of the $2.34M target) as of the latest filing. David is listed as director, executive officer on 7 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AP
Biotechnology

Ayala Pharmaceuticals, Inc.

Monmouth Junction, NJ · Apr 28, 2021 → Nov 2, 2023 · 3 filings
  • Nov 2, 2023 · D · $433,825 sold of $433,825 · 3 investors · min. No minimum reported · role: Director (Chair of Board) EDGAR ↗
  • Feb 11, 2022 · D · $4,750,000 sold of $4,750,000 · 6 investors · min. $380,000 · role: Director EDGAR ↗
  • Apr 28, 2021 · D · $11,093,521 sold of $11,093,521 · 2 investors · min. $3,000,000 · role: Director EDGAR ↗

Raised $11.1M from 29 investors (100% of the $434K target) as of the latest filing. David is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

IB
Pooled Investment Fund · group: Israel Biotech

Israel Biotech Fund II, L.P.

Rehovot, Israel (as filed: L3) · Jul 24, 2019
  • Jul 24, 2019 · D · $65,000,000 sold of $100,000,000 · 44 investors · min. No minimum reported · role: Executive Officer (Director of the General Partner of the General Partner) EDGAR ↗

Raised $65M from 44 investors (65% of the $100M target) as of the latest filing. David is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

TB
Biotechnology

TAMIR BIOTECHNOLOGY, INC.

Short Hills, NJ · Nov 2, 2009 → Jan 25, 2018 · 5 filings
  • Jan 25, 2018 · D · $808,638 sold of $1,500,000 · 3 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 30, 2016 · D/A · $1,722,476 sold of $1,722,476 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 20, 2016 · D · $1,524,978 sold of $1,622,477 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 10, 2015 · D · $800,000 sold of $800,000 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 2, 2009 · D · $3,250,000 sold of $3,250,000 · 8 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $3.25M from 9 investors (100% of the $1.5M target) as of the latest filing. David is listed as director on 5 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

GP
Pharmaceuticals

Galmed Pharmaceuticals Ltd.

Tel Aviv, Israel (as filed: L3) · Aug 15, 2017
  • Aug 15, 2017 · D · $100,000 sold of $350,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $100K from 1 investor (29% of the $350K target) as of the latest filing. David is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

IB
Pooled Investment Fund · group: Israel Biotech

Israel Biotech Fund I, L.P.

Tel Aviv, Israel (as filed: L3) · Oct 22, 2015
  • Oct 22, 2015 · D · $0 sold of $100,000,000 · 0 investors · min. No minimum reported · role: Executive Officer (Director of the general partner of the General Partner.) EDGAR ↗

No sales reported yet as of the latest filing. David is listed as executive officer.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

CO
Biotechnology

CHAMPIONS ONCOLOGY, INC.

Hackensack, NJ · Feb 7, 2013 → Mar 25, 2015 · 2 filings
  • Mar 25, 2015 · D · $14,000,000 sold of $14,000,000 · 11 investors · min. $1 · role: Director EDGAR ↗
  • Feb 7, 2013 · D · $9,300,000 sold of $9,300,000 · 7 investors · min. $1 · role: Director EDGAR ↗

Raised $14M from 13 investors (100% of the $14M target) as of the latest filing. David is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

IP
Pharmaceuticals

IMMUNE PHARMACEUTICALS INC

New York, NY · Apr 14, 2014
  • Apr 14, 2014 · D · $11,720,475 sold of $11,720,475 · 42 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $11.7M from 42 investors (100% of the $11.7M target) as of the latest filing. David is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AT
Biotechnology

Akari Therapeutics Plc

Tampa, FL · Apr 13, 2012 → Sep 30, 2013 · 4 filings
  • Sep 30, 2013 · D · $12,516,232 sold of $12,516,232 · 18 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 1, 2013 · D · $931,000 sold of $10,000,000 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 13, 2012 · D/A · $1,503,000 sold of $1,503,000 · 20 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 13, 2012 · D · $0 sold of $1,100,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $75M from 62 investors (100% of the $12.5M target) as of the latest filing. David is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(c) (163 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

YL
Biotechnology

Y Labs, Inc.

Baltimore, MD · Aug 26, 2013
  • Aug 26, 2013 · D · $1,000 sold of Indefinite · 1 investors · min. $10,000 · role: Executive Officer, Director EDGAR ↗

Raised $1,000 from 1 investor as of the latest filing. David is listed as executive officer, director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

RG
Biotechnology

Rosetta Genomics Ltd.

Rehovot, Israel (as filed: L3) · Mar 3, 2011 → Feb 9, 2012 · 6 filings
  • Feb 9, 2012 · D · $1,750,000 sold of $1,750,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 1, 2011 · D · $1,518,751 sold of $1,948,501 · 21 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 7, 2011 · D/A · $2,725,000 sold of $2,725,000 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 7, 2011 · D/A · $2,500,000 sold of $2,500,000 · 17 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 3, 2011 · D · $2,725,000 sold of $2,725,000 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 3, 2011 · D · $2,500,000 sold of $2,500,000 · 17 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $2.73M from 21 investors (100% of the $1.75M target) as of the latest filing. David is listed as director on 6 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

KV
Pharmaceuticals

K-V Pharmaceutical Co

Chesterfield, MO · Dec 6, 2010 → Apr 1, 2011 · 3 filings
  • Apr 1, 2011 · D · $225,000,000 sold of $225,000,000 · 104 investors · min. $65,000 · role: Director EDGAR ↗
  • Mar 4, 2011 · D · $32,337,500 sold of $32,337,500 · 12 investors · min. $55,250 · role: Director EDGAR ↗
  • Dec 6, 2010 · D · $7,552,506 sold of $7,552,506 · 2 investors · min. $2,492,327 · role: Director EDGAR ↗

Raised $260.9M from 104 investors (100% of the $225M target) as of the latest filing. David is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

People around David 40

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.

KB
No photo found yet (own website and image search run after this page is viewed)
Person

Kenneth Berlin

Executive Officer, Director · 8 shared filings (2 issuers)

Listed on the same filings as David Sidransky. Their page shows their other deals.

TE
No photo found yet (own website and image search run after this page is viewed)
Person

Tali Yaron-Eldar

Director · 7 shared filings (2 issuers)

Listed on the same filings as David Sidransky. Their page shows their other deals.

YA
No photo found yet (own website and image search run after this page is viewed)
Person

Yaron Adler

Director, Executive Officer · 7 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as David Sidransky. Their page shows their other deals.

VC
No photo found yet (own website and image search run after this page is viewed)
Person

Vered Caplan

Executive Officer, Director · 7 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as David Sidransky. Their page shows their other deals.

RA
No photo found yet (own website and image search run after this page is viewed)
Person

Ranit Aharonov

Executive Officer · 6 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

BM
No photo found yet (own website and image search run after this page is viewed)
Person

Brian A Markison

Director · 6 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

JR
No photo found yet (own website and image search run after this page is viewed)
Person

Joshua Rosensweig

Director · 6 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

GD
No photo found yet (own website and image search run after this page is viewed)
Person

Gerald Dogon

Director · 6 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

GY
No photo found yet (own website and image search run after this page is viewed)
Person

Guy Yachin

Director · 6 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as David Sidransky. Their page shows their other deals.

AS
No photo found yet (own website and image search run after this page is viewed)
Person

Ana I. Stancic

Director · 5 shared filings (3 issuers)

Listed on the same filings as David Sidransky. Their page shows their other deals.

TK
No photo found yet (own website and image search run after this page is viewed)
Person

Tzipora Shoshani Kupitz

Executive Officer · 5 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

KG
No photo found yet (own website and image search run after this page is viewed)
Person

Keren Givli

Executive Officer · 5 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

AC
No photo found yet (own website and image search run after this page is viewed)
Person

Ayelet Chajut

Executive Officer · 5 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

TJ
No photo found yet (own website and image search run after this page is viewed)
Person

Tami Fishman Jutkowitz

Executive Officer · 5 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

IB
No photo found yet (own website and image search run after this page is viewed)
Person

Isaac Bentwich

Director · 5 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

PW
No photo found yet (own website and image search run after this page is viewed)
Person

Paul Weiss

Director · 5 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

AN
No photo found yet (own website and image search run after this page is viewed)
Person

Ashish Nanda

Director, Executive Officer · 5 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

MC
No photo found yet (own website and image search run after this page is viewed)
Person

Mark Cohen

Director · 4 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as David Sidransky. Their page shows their other deals.

RV
No photo found yet (own website and image search run after this page is viewed)
Person

Racheli Vizman

Executive Officer · 4 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as David Sidransky. Their page shows their other deals.

YC
No photo found yet (own website and image search run after this page is viewed)
Person

Yoav Chelouche

Director · 4 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

MM
No photo found yet (own website and image search run after this page is viewed)
Person

Moshe Many

Director · 4 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

TE
No photo found yet (own website and image search run after this page is viewed)
Person

Tina Edmonston

Executive Officer · 4 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

SY
No photo found yet (own website and image search run after this page is viewed)
Person

Saul Yedgar

Executive Officer, Director · 4 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

DE
No photo found yet (own website and image search run after this page is viewed)
Person

Dov Elefant

Executive Officer · 4 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

JL
No photo found yet (own website and image search run after this page is viewed)
Person

Johnson Lau

Director · 4 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as David Sidransky. Their page shows their other deals.

AE
No photo found yet (own website and image search run after this page is viewed)
Person

Amos Eiran

Director · 4 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

FK
No photo found yet (own website and image search run after this page is viewed)
Person

Fred Knoll

Director · 4 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as David Sidransky. Their page shows their other deals.

JB
No photo found yet (own website and image search run after this page is viewed)
Person

Joanne Barsa

Executive Officer · 4 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

JS
No photo found yet (own website and image search run after this page is viewed)
Person

Jamie Sulley

Executive Officer, Director · 4 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

NR
No photo found yet (own website and image search run after this page is viewed)
Person

Neil Reithinger

Executive Officer · 4 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

MP
No photo found yet (own website and image search run after this page is viewed)
Person

Mario Philips

Director · 4 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

RA
No photo found yet (own website and image search run after this page is viewed)
Person

Roni A. Appel

Director · 3 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

JL
No photo found yet (own website and image search run after this page is viewed)
Person

Joseph D. Lehrer

Director · 3 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

TM
No photo found yet (own website and image search run after this page is viewed)
Person

Thomas McHugh

Executive Officer · 3 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

DH
No photo found yet (own website and image search run after this page is viewed)
Person

David S. Hermelin

Director · 3 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

GB
No photo found yet (own website and image search run after this page is viewed)
Person

Gregory S. Bentley

Executive Officer, Director · 3 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

GD
No photo found yet (own website and image search run after this page is viewed)
Person

Gregory J. Divis, Jr.

Executive Officer · 3 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

RB
No photo found yet (own website and image search run after this page is viewed)
Person

Robert E. Baldini

Director · 3 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

MD
No photo found yet (own website and image search run after this page is viewed)
Person

Mark A. Dow

Director · 3 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

YC
No photo found yet (own website and image search run after this page is viewed)
Person

Yuval Cohen

Executive Officer, Director · 3 shared filings (1 issuer)

Listed on the same filings as David Sidransky. Their page shows their other deals.

The team behind the deals

IB
Sponsor group

Israel Biotech

2 issuers · 2 filings · $65M reported sold · 2015–2019

One team, 2 deal companies. David Sidransky is listed on 2 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name David Sidransky.

Same business address

38 other issuers file from the same address

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Adviser registration (Form ADV)

None of the 12 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to David Sidransky by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 12 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers David Sidransky is listed on: none on file. No website or social profile named in Israel Biotech Fund II, L.P.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #232,188 of 374,652 in line (14 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Rehovot, L3). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn people search ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗New Jersey state courts — find the court ↗Missouri Case.net ↗Maryland Judiciary case search ↗New York WebCivil Supreme ↗California — find the county court ↗Los Angeles Superior Court case search ↗Hillsborough County FL Clerk (HOVER) ↗Miami-Dade Clerk online case search ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

New Jersey Secretary of State business search ↗Missouri Secretary of State business search ↗Maryland Secretary of State business search ↗New York Secretary of State business search ↗California Secretary of State business search ↗Florida Secretary of State business search ↗OpenCorporates ↗

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when David Sidransky appears on a new Form D, or when a court case or SEC action is matched to them. See plans →